Tsinghua University-China National Pharmaceutical Group Co., Ltd. Joint Institute for Pharmaceutical Innovation is a high-level collaborative innovation platform integrating industry, academia, and research, jointly established by Tsinghua University and China National Pharmaceutical Group Corporation (Sinopharm), a leading enterprise in China's pharmaceutical industry. It was officially inaugurated in April 2024. The establishment of the institute represents a significant initiative by both parties to implement the national strategy of "prioritizing the people's life and health," marking a new phase of deepened university-enterprise collaboration.

As a powerful alliance between national strategic scientific capabilities and an industry leader, the institute leverages Tsinghua University's multidisciplinary research strengths and top-tier talent pool, combined with Sinopharm's comprehensive resources across the entire pharmaceutical industrial chain and industrial transformation capabilities. It focuses on cutting-edge technological breakthroughs, innovative transformation, and high-end talent cultivation in biomedicine. Through building a full-chain innovation system encompassing "basic research—technology development—clinical translation," the institute aims to address critical scientific challenges hindering pharmaceutical development and foster original breakthroughs with global impact. Targeting the creation of a national-level innovation hub, it seeks to establish new paradigms for deep integration of industry, academia, and research, accelerating China's transition from a pharmaceutical manufacturing powerhouse to an innovation-driven leader, thereby advancing the Healthy China initiative.

According to strategic plans, the institute will pursue breakthroughs in core biopharmaceutical technologies and emerge as a key global rule-maker in the pharmaceutical sector through forward-looking research layout, open innovation ecosystems, and enhanced international cooperation. This collaborative innovation entity not only provides an industrialization platform for Tsinghua's research outcomes but also injects new momentum into Sinopharm's original innovation capabilities, pioneering a new model of cooperation between top universities and central state-owned enterprises to serve national strategic needs.